Develops anti-inflammatory therapies for the treatment of complement-mediated diseases, focusing on improving outcomes for patients with rare and severe inflammatory conditions.
InflaRx N.V., headquartered in Jena, Germany, is a dynamic clinical-stage biopharmaceutical company at the forefront of discovering and developing innovative inhibitors using C5a technology. Operating primarily in Germany and the United States, InflaRx focuses on leveraging its expertise in C5a, an inflammatory mediator implicated in various autoimmune and inflammatory diseases. The company's flagship product candidate, vilobelimab, represents a groundbreaking intravenously delivered anti-C5a monoclonal antibody that has completed Phase III clinical trials for treating hidradenitis suppurativa and is advancing through Phase II trials for conditions such as anti-neutrophil cytoplasm antibody associated vasculitis and pyoderma gangraenosum.
In addition to vilobelimab, InflaRx is actively developing INF904, an oral small molecule targeting undisclosed chronic inflammatory and autoimmune diseases, as well as IFX002, currently in pre-clinical stages for addressing chronic inflammation and autoimmune conditions. The company operates with strategic partnerships, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc., underscoring its commitment to advancing therapeutic solutions through collaborative efforts.
Founded in 2007 as Fireman B.V. and later rebranded as InflaRx N.V. in 2017, the company has rapidly grown to prominence within the biopharmaceutical industry. With a robust pipeline and a focus on pioneering treatments for severe and rare diseases, InflaRx continues to drive innovation in the field of immunology and autoimmune disorders, aiming to transform patient care and improve outcomes globally.